Feasibility of whole body vibration during intensive chemotherapy in patients with hematological malignancies – a randomized controlled pilot study

Antonia Pahl 1*, Anja Wehrle 2, Sarah Kneis 1, Albert Gollhofer 3 and Hartmut Bertz 1

Abstract

Background: Hospitalized cancer patients undergoing intensive or high-dose chemotherapy often experience a considerable decline in functional performance associated with the increased risk of adverse health events. Exercises, particularly resistance-based exercises that may counteract this decline are restricted by therapy-related side effects. Since whole body vibration (WBV) is known to efficiently stimulate the neuromuscular system without significantly raising blood pressure, we hypothesize that especially WBV is particularly feasible even during intensive or high-dose chemotherapy (primary endpoint) and thus induces beneficial functional adaptations.

Methods: Twenty hospitalized patients with hematological malignancies scheduled for intensive or high-dose chemotherapy were randomly allocated to an intervention group (IG) undergoing WBV, or an active control group (CG) cycling. Feasibility was determined by comparing the IG’s and CG’s training compliance. Furthermore, to assess feasibility, WBV-induced changes in chemotherapy-related side effects, blood pressure, and heart rate immediately after exercising were documented. To assess patients’ functional performance, we measured jump height (cm), the duration (sec) of performing the chair rising- (CRT) and timed-up-and-go test (TUG), maximum power output during jumping and CRT (watt/kg) as well as sway path (mm) during balance tasks.

Results: Training compliance was similar between groups (IG: median 62%, range 39–77; CG: 67%, 58–100; p = 0.315). Moreover, we observed neither the IG’s reported side effects worsening, nor any increase in blood pressure after WBV. IG’s jump height (+2.3 cm, 95%CI 0.1–4.4, p = 0.028) and TUG performance (−1.3 s, 95%CI -2.53 − -0.65, p = 0.027) improved significantly, while sway paths in semi-tandem stance were augmented after the intervention (eyes open: +60 mm, 95%CI 2–236, p = 0.046; eyes closed: +88 mm, 95%CI 49–214, p = 0.028). The CG’s performances did not change over time. Maximum power output during CMJ and CRT and time during CRT did not change.

Conclusion: Our study is the first proving the feasibility of WBV during intensive/high-dose chemotherapy of hospitalized cancer patients. Additionally, WBV-induced neuromuscular adaptations resulted in functional benefits relevant to patients’ autonomy. We believe that WBV can be implemented as an alternative training method during intensive chemotherapy, although the relative benefit compared to conventional resistance training requires more evaluation in future studies.

Trial registration: German Register of Clinical Trials No.: DRKS00004338, prospectively registered on 11/30/2012.

Keywords: Exercise therapy, Postural balance, Cancer therapy, Acute leukemia, Bone marrow neoplasm, Intervention study, Activities of daily living

* Correspondence: antonia.pahl@uniklinik-freiburg.de
1Department of Medicine I (Specialties: Hematology, Oncology, and Stem-Cell Transplantation), Faculty of Medicine, Medical Center – University of Freiburg, Hugstetterstr. 55, 79106 Freiburg, Germany

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Many patients diagnosed with hematologic malignancies (e.g. leukemia) undergo intensive or high-dose chemotherapy [1, 2] leading to cytopenia and other side effects [3, 4]. These are manifold and can impair physical and psychological functioning considerably. Because of the growing risk of complications due to aplasia (e.g. infections, bleeding), patients are usually hospitalized for two to 4 weeks, meaning a period of restricted mobility associated inter alia with muscle-mass loss, and reduced strength capacity and functional performance [5, 6]. It is common knowledge that impaired functional performance and poor body composition, i.e. disproportionally less muscle mass, limit patients' autonomy and quality of life [7, 8] and may raise the mortality risk [9–11]. All cancer patients are therefore recommended to be physically active during treatment while considering specific limitations to counteract physical deconditioning and preserve mobility [12–14]. There is evidence that exercising (e.g. aerobic exercises, especially cycling) even during high-dose chemotherapy (as conditioning therapy prior to allogeneic hematopoietic cell transplantation) is safe and effective, and has the potential to reduce physical and psychosocial side effects [13, 15–19]. However, aerobic exercises alone appear insufficient to affect functional impairments especially, whereas some studies added resistance training to their intervention program [19–21]. They confirmed the feasibility of resistance training during chemotherapy and demonstrated positive effects on patients' physical functioning, but could not entirely maintain muscle strength during hospitalization. Taking into account catabolic medication [22, 23] and the amount of time patients are exposed to bed rest, high intensities and volumes of resistance training were needed to significantly avoid losing strength [24] and its functional consequences, factors that are relevant prognostic factors for survival [11]. However, according to current recommendations [14, 25] patients’ blood values, i.e. platelets counts, and well-being may limit the intensity and volume of resistance training patients are able to perform during intensive chemotherapy.

We therefore planned to introduce whole body vibration (WBV) as a resistance training method for patients undergoing intensive chemotherapy during hospital stay. WBV induces frequency-dependent repeating contractions of the muscles culminating in a tonic vibration reflex that enhances the recruitment of motor units [26, 27]. WBV thus reveals EMG activity similar to that during conventional squat exercises with external loads [28]. It thus stimulates the musculoskeletal system very time-efficiently and can improve muscle strength [29] and functional performance [30]. Furthermore, it evidently prevents muscle-mass loss during bed rest [6, 31]. With all these effects, WBV has little impact on vital parameters, e.g. blood pressure [32, 33]. We therefore believe that WBV is feasible even for patients during thrombocytopenia. Additionally, it might be less tiring and easier to carry out, but similarly effective to resistance training because of the high neuromuscular activity even under passive conditions when following current recommendations [14]. Up to now, results of WBV’s feasibility or effectiveness are only available to cancer patients after active anti-cancer treatment [34–36]. There is only one ongoing study [37] investigating WBV during chemotherapy, but no results have yet been published. We thus implemented a randomized controlled pilot study to assess primarily the feasibility of WBV during intensive and high-dose chemotherapy during hospital stay. Since aerobic exercise has proven to be safe and feasible for hospitalized patients during high-dose chemotherapy [16, 38] we aimed to compare exercise's feasibility of WBV versus an active control group performing aerobic cycling exercises. Secondly, we attempted to evaluate WBV-induced effects on patient's functional performance. We hypothesized that patients would adhere to the WBV exercise sessions as prescribed despite therapy-related side effects without exhibiting differences from the control group. Furthermore, WBV might induce neuromuscular adaptations leading to functional benefits.

Methods
Study design and patients
The main objective of this randomized controlled pilot study was to confirm WBV’s feasibility in hospitalized patients with hematological malignancies undergoing intensive or high dose chemotherapy. Patients were recruited at the Department of Medicine I, University Medical Center Freiburg, Germany, immediately after hospital admission. Within a 7-month time frame, eligible patients were randomly allocated to either an intervention group (IG) or active control group (CG). Block randomization was based on a computer-assisted pseudo-random number generator (Research Randomizer, Version 4.0). Inclusion criteria were diagnosis of a hematological malignancy, scheduled for intensive/high-dose chemotherapy with a two- to four-week period of hospitalization, and written informed consent. Absolute exclusion criteria were any unstable bone metastasis, a knee or hip endoprosthesis, epilepsy, pacemaker, severe cardiovascular diseases [36, 39] and threshold blood-count values below safety criteria (platelets count ≤10,000/μl and hemoglobin ≤8 g/dl) [40, 41]. Relative exclusion criteria included stents or former joint injuries. Baseline parameters were assessed before the first administration of chemotherapy (T0) and post-evaluated immediately before discharge (T1), respectively. Table 1 summarizes patients’ clinical information. The study was
approved by the Ethics Committee of the University of Freiburg and conducted according to the Declaration of Helsinki (German Register of Clinical Trials No.: DRKS00004338).

**Intervention**

Both groups’ one-on-one training sessions took place in a separate room on the patients’ ward during three sessions per week, each lasting 20 min.

The IG’s exercise protocol included three sets of two to four different exercises (static and dynamic squats, heel raise and combination of both) on the Galileo® Sport vibration platform (Novotec Medical GmbH, Pforzheim, Germany) which is adjustable in steps of 0.5 Hz within a range of 5–30 Hz. Each exercise lasted 30 to 60s depending on patients’ condition with a 30 to 60s rest between exercises and 60 to 120 s between sets. Patients should reach intensity prescription of 14 to 16 on the perceived exertion rating scale (Borg 6–20) [40, 42]. To generate the best neuromuscular response, exercises were performed within a frequency range of 18–25 Hz and at 3.5–4 mm amplitude [43, 44]. During static exercises, patients were asked to shift their body weight on their forefeet and to maintain a knee angle of approx. Sixty degrees flexion in static position [43]. If patients couldn’t maintain the forefoot position

| Table 1 | Clinical information of completer (n = 11) and all randomized patients (n = 20, completer and drop-outs) |
|---------|-----------------------------------------------------------------------------------------------------|
|         | Completers (n = 20, completer and drop-outs) | All (n = 20) |
| IG n = 6 | CG n = 5 |
| Age [years]a | 47 (19–62) | 56 (32–63) | 55 (47–63) |
| Sex [n] male:female | 5:1 | 3:2 | 14:6 |
| BMI [kg/m²]a | 26 (20–28) | 26 (22–28) | 26 (25–27) |
| Diagnosis [n] | | | |
| AML | 1 | 4 | 8 |
| ALL | 1 | 0 | 1 |
| APL | 1 | 0 | 1 |
| NHL | 2 | 0 | 5 |
| HL | 0 | 0 | 1 |
| t-cell lymphoma | 1 | 0 | 1 |
| MW | 0 | 0 | 1 |
| MM | 0 | 1 | 1 |
| PMF | 0 | 0 | 1 |
| Remission [n] | | | |
| ED | 1 | 3 | 7 |
| SD | 0 | 1 | 2 |
| PD | 1 | 0 | 1 |
| CR | 0 | 1 | 2 |
| PR | 0 | 0 | 1 |
| recurrence | 2 | 0 | 5 |
| N/A | 2 | 0 | 2 |
| Time since initial diagnosis [weeks]a | 46 (2–371) | 6 (2–215) | 32 (7–128) |
| Cycles of chemotherapy before admission [n]a | 9 (0–16) | 1 (0–9) | 4 (1–9) |
| Type of chemotherapy during intervention [n] | | | |
| High-dose prior to autologous HSCT | 1 | 1 | 5 |
| Induction therapy for AML | 4 | 3 | 8 |
| Intensive chemotherapy for ALL, HL, NHL | 1 | 1 | 7 |
| Duration of hospitalization [days]a | 27 (21–56) | 27 (16–69) | 26 (22–34) |
| Karnofsky performance index [%]a | 95 (80–100) | 90 (80–100) | 90 (85–90) |

*Median (range), BMI body mass index, AML acute myeloid leukemia, ALL acute lymphocytic leukemia, APL acute promyelocytic leukemia, NHL non-Hodgkin lymphoma, HL Hodgkin lymphoma, MW morbus Waldenström, MM multiple myeloma, PMF primary myelofibrosis, ED initial diagnosis, SD stable disease, PD progress disease, CR complete remission, PR partial remission, HSCT hematopoietic cell transplantation*
throughout the exercise period, we supported their stance position via a heel foam wedge.

The CG performed aerobic exercises on a bicycle ergometer. Exercise sessions also lasted up to 20 min with the same intensity prescription as the IG. For patients unable to endure 20 min continuous cycling, an individual interval program with periods of rest was used to achieve 20 min cycling in total for each exercise session.

We consulted patients’ files for blood values before each exercise session to ensure their values met our safety criteria: platelets count ≥10.000/μl and hemoglobin ≥8 g/dl. Additionally, we controlled patients’ blood pressure and heart rate before and after each exercise session to avoid overload. Blood values, blood pressure, training progress and reasons for missed sessions were documented.

Outcome measures
Primary endpoint feasibility
We determined the feasibility of WBV by comparing the IG’s and CG’s training compliance. Training compliance in percent was calculated as completed exercise sessions divided by planned exercise sessions.

Furthermore, exercise-related adverse events were documented and reasons for missed exercise sessions were compared between groups. The tolerability of vibration training was also assessed via a self-designed questionnaire that asked (a) for the extent of chemotherapy-induced side effects (concerning pain, illness, dizziness, etc.) immediately before and after each vibration training session to examine whether WBV might enhance or weaken these side effects and (b) to determine their WBV-induced well-being. This questionnaire included 18 items scored from 0 to 3 (not at all, marginally, quite a lot, very much). Additionally, blood pressure and heart rate were measured and documented immediately before and after exercising as well as at the two measurement sessions (T0 and T1).

Secondary endpoint functional performance
All functional performance measurements were taken on a force plate (Leonardo Mechanograph GRFP, Novotec Medical GmbH, Pforzheim, Germany) that determined dynamic ground reaction forces in its local and temporal progress. Data were recorded with a sample rate of 800 Hz and analyzed using Leonardo Mechanograph Research-Software (Novotec Medical GmbH, Pforzheim, Germany).

To test functional performance under dynamic conditions, two common functional tasks were performed: a maximum counter-movement jump (CMJ) and a chair-rising test (CRT). Both tests evaluate leg muscle power output which in turn reflects the efficiency of lower limb neuromuscular interaction [45]. Patients executed CMJ with freely-moving arms and were instructed to jump as high as possible. Outcomes were defined as maximum power output during take-off per kilogram body weight (\(P_{\text{max,CMJ}}\) W/kg) and jumping height (cm). For CRT, patients started in a sitting position with their arms crossed over their chest. Patients had to stand up from a bench (45 cm, Novotec Medical GmbH) and sit down again five times in a row. They were asked to rise up until full extension of the knee and hip and to sit down using their full bodyweight. Durations (sec) of the second, third and fourth repetition were recorded and the average duration was calculated of one repetition [46]. Additionally, power output during stand up (\(P_{\text{max,CRT}}\) W/kg) was measured for the CRT. Best values out of two trials per test condition were used to analyze CMJ and CRT.

Functional performance under static conditions was evaluated by changes in balance performance, known to indicate neuromuscular and functional impairments [47, 48]. We determined the center of force (COF) displacement in antero-posterior and medio-lateral direction during three different stance conditions: semi-tandem stance with eyes open (EO) and eyes closed (EC) and one-leg stance in EO condition. Assessments took place without shoes. Patients were asked to stand upright and comfortably and direct their gaze onto a marked spot located at eye level on the wall. Sway path (mm) and standard ellipse (cm²) of COF was recorded over a period of 30s. The mean value out of three trials was used for analysis.

Secondary endpoint mobility
To assess basic functional mobility in a daily situation, we used the timed-up-and-go test (TUG) commonly used to evaluate patients’ autonomy in daily life [49]. Duration (sec) was recorded from the moment patients got up from an armed chair, walked three meters, turned around, walked back and sat down on the chair again [49, 50].

Statistics
All variables were included in non-parametric analysis as the assumption of normal distribution (Shapiro-Wilk test) was not satisfied and the sample size is small. Differences in training compliance between both groups and differences of groups’ delta (T1-T0) were assessed by Mann-Whitney-U-test. Intragroup differences over time were computed by Wilcoxon signed-rank test. The level of significance was set to \(p < 0.05\). Group data are presented as median and 95% confidence interval (95% CI). To estimate the treatment effect the point estimate and 95% confidence interval of the Hodges-Lehmann’s median differences for paired groups were used. All statistical analyses were conducted using IBM SPSS Version 22 software (SPSS Inc., Chicago, Illinois, USA).
Results
No adverse events were observed during the study period. No baseline assessment was possible in three CG patients. Thus 17 patients participated in our intervention program and were included in the feasibility analysis. However, no post-intervention data on two CG and four IG patients were available (Fig. 1). Eleven patients were thus ultimately included in our functional performance and mobility analyses.

Feasibility
No adverse events or differences in groups’ training compliance were observed during any of the WBV training sessions (IG: 62%, CG: 67%, \( p = 0.315 \)) (Table 2 and Fig. 2a). Reasons for missed exercise sessions were similar between groups (Table 2) and no training session had to be cancelled due to the type of exercise. Furthermore, WBV training did not worsen subjective chemotherapy-induced side effects: \(-0.02\) (a difference of 0 would represent no
change in chemotherapy-induced side effects after training compared to pre-training, while 3 would represent a great increase). Additionally, 63% of IG patients experienced WBV as “quite good”, 30% as “very good”, 7% as “marginally good” and 0% feedback “not good at all” (Fig. 2b). We observed no changes in either group in their blood pressure or heart rate values post-exercising compared to pre-exercising as well as post-intervention compared to pre-intervention (Table 3).

Functional performance
IG patients improved their jump height significantly (2.3 cm, 95% CI 0.1–4.4, p = 0.028), while the CG’s jump height was unchanged (~3.3 cm, 95% CI -13.0–3.6, p = 0.345). Power output (P\text{max}_{\text{CMJ}}) of both groups remained stable over time. No changes after intervention were observed either in any group (IG or CG) for the duration of CRT or in their power output during CRT (P\text{max}_{\text{CRT}}).

During balance tasks, only the IG’s sway path in the semi-tandem stance conditions was augmented after intervention (EO: 60 mm, 95% CI 2–236, p = 0.046; EC: 88 mm, 95% CI 49–214, p = 0.028). The monopedal stance revealed no changes. All the CG’s balance performances were unchanged. Furthermore, our analysis of standard ellipse revealed no inter- or intra-group changes. All functional-performance results are illustrated in Table 4.

Mobility
IG patients reduced the time they needed to do the TUG test (~1.3 s, 95% CI -2.53 – -0.7, p = 0.027), while the CG revealed no change (~1.1 s, 95% CI -6.4 – 1, p = 0.138) (see Table 4).
Table 3 Changes in vital parameters and weight

|                | n | T0* median (range) | n | T1* median (range) | median difference (95% CI) | P    |
|----------------|---|--------------------|---|--------------------|----------------------------|------|
| **Blood pressure** |   |                    |   |                    |                            |      |
| Systolic (mmHg) | IG 6 | 128 (110–145)      | 6 | 110 (100–123)      | −20 (−43–0)                | 0.068|
|                | CG 5 | 120 (115–130)      | 5 | 110 (105–125)      | −8 (−20–5)                  | 0.141|
|                | P    | 0.662              |    | 0.537              |                            | 0.662|
| Diastolic (mmHg)| IG 6 | 80 (70–90)         | 6 | 70 (70–80)         | −8 (−15–3)                 | 0.102|
|                | CG 5 | 80 (60–85)         | 5 | 75 (70–90)         | 0 (−5–15)                  | 0.705|
|                | P    | 0.662              |    | 0.247              |                            | 0.177|
| Heart rate (bpm)| IG 6 | 81 (64–97)         | 6 | 94 (71–100)        | 11 (−11–22)                | 0.345|
|                | CG 5 | 92 (76–100)        | 5 | 80 (76–90)         | −5 (−22–13)                | 0.225|
|                | P    | 0.329              |    | 0.537              |                            | 0.177|
| Weight (kg)    | IG 6 | 76 (67–80.3)       | 6 | 74.4 (66–83.5)     | 0.1 (−2.5–3.2)             | 0.917|
|                | CG 5 | 80 (71.8–91)       | 5 | 77 (73–80)         | −2.2 (−12–1.2)             | 0.144|
|                | P    | 0.247              |    | 0.662              |                            | 0.247|

|                | n | Before exercise session* median (range) | n | After exercise session median (range) | median difference (95% CI) | P    |
|----------------|---|----------------------------------------|---|---------------------------------------|----------------------------|------|
| **Blood pressure** |   |                                        |   |                                        |                            |      |
| Systolic (mmHg) | IG 6 | 118 (112–137)                       | 6 | 118 (113–135)                        | 0.5 (−4–3)                | 0.686|
|                | CG 5 | 114 (112–127)                       | 5 | 119 (111–136)                        | 4 (−1–9)                  | 0.078|
|                | P    | 0.792                                |    | 1.000                                |                            | 0.082|
| Diastolic (mmHg)| IG 6 | 79 (68–86)                           | 6 | 78 (73–83)                           | 0 (−3–5)                 | 0.893|
|                | CG 5 | 76 (71–82)                           | 5 | 77 (71–84)                           | 1 (0–3)                  | 0.068|
|                | P    | 0.792                                |    | 0.931                                |                            | 0.429|

*Median (range); bpm beats per minute

**Discussion**

Aim of our prospective, randomized controlled pilot study was to prove for the first time the feasibility of WBV training for hospitalized cancer patients during intensive or high-dose chemotherapy. We did not observe any WBV-related adverse events, the groups’ training compliance and reasons for missed exercise sessions were similar, and patients did not report any worsening of chemotherapy-related side effects after WBV sessions. Furthermore, as previously assumed, blood pressure was nearly unaffected by WBV. We thus succeeded in proving the feasibility of WBV in this setting and have justified its application in subsequent investigations evaluating its relative benefits. Additionally, we detected functional benefits due to WBV, indicated by their improved jumping- and TUG performance. Although our intervention did not lead to significant differences between groups over the intervention period, our results indicate that WBV may counteract some functional worsening during chemotherapy.

Due to the loss of physical capacity during treatment [16, 38], cancer patients are encouraged to be physically active to preserve their functional status [12, 14] and to reduce the risk of adverse health outcomes [11]. Aerobic exercise is well-researched, and it is safe and effective for cancer patients even during most intensive treatments [16, 38]. However, in light of muscle-mass loss and a considerable decline in functional performance [18], intensive and functional-oriented resistance exercises might counteract those impairments more effectively than aerobic exercises. In general, a patient’s condition and potential therapy-related side effects like cytopenia i.e. thrombocytopenia will undoubtedly limit the intensity and volume of resistance training, especially in those undergoing intensive chemotherapy [14]. Thus, resistance training during chemotherapy usually consists of exercises with therabands and body weight in combination with aerobic exercises [19, 53, 54]. To date, there is only one randomized controlled study [21] investigating the effect of exclusively resistance training on cancer patients during chemotherapy. However, that study focused solely on the effects on protein metabolism and did not analyze functional performance [21]. Resistance training with high intensity and great neuromuscular impact would be most effective to counteract muscle mass loss during long periods of inactivity [55]. Indeed, this is associated with a rise in blood pressure [56, 57] that increases the risk of bleeding when patient’s platelets are low. Furthermore, it usually requires that participants be willing to actively exhaust themselves in a state of physical discomfort. Thus, considering a patient’s physical
and mental condition in line with current guidelines [14, 40], high intensity resistance training during intensive chemotherapy is not feasible. On the other hand, WBV is a strengthening exercise method known to increase muscle power output even under passive training conditions by inducing a tonic-vibration reflex addressing many muscle fibers simultaneously [26, 29]. Additional exercises like the static and dynamic squats our patients also performed can further intensify muscular activity [58]. Furthermore, WBV-induced periodic dynamic movements cause increased blood flow, potentially inhibiting a rise in blood pressure [33]. Thus, WBV has less impact on vital

| Table 4 Results of functional performance and mobility |
|-----------------------------------------------|
|                                              |
| Functional performance                        |
|                                              |
| Jumping height (cm)                          |
| IG  6  24.9 (24.5–45.0)  &  6  28.0 (26.1–45.2)  &  2.3 (0.1–4.4)  &  0.028*  |
| CG  5  25.6 (20.6–36.5)  &  5  24.4 (18.3–33.1)  &  –3.3 (–13.0–3.6)  &  0.345  |
| P  0.792  &  0.329  &  0.126  |
|                                              |
| Pmax,CMJ (W/kg)                              |
| IG  6  26.3 (23.5–44)  &  6  25.3 (25–45.3)  &  –0.9 (–3.9–1.4)  &  0.345  |
| CG  5  28.1 (24.8–28.1)  &  5  28.6 (20.9–30.8)  &  –0.6 (–14.5–2.7)  &  0.500  |
| P  0.662  &  0.792  &  1.00  |
|                                              |
| Duration_CRT (sec)                           |
| IG  6  1.9 (1.2–2.8)  &  6  1.8 (1.1–2.9)  &  –0.0 (–0.2–0.2)  &  0.686  |
| CG  5  2.5 (1.9–3.4)  &  5  2.5 (1.5–3.7)  &  –0.0 (–0.6–0.6)  &  0.686  |
| P  0.247  &  0.427  &  1.00  |
|                                              |
| Balance performance                          |
|                                              |
| STEO sway path (mm)                          |
| IG  6  549 (447–591)  &  6  579 (457–713)  &  60 (2–236)  &  0.046*  |
| CG  5  498 (333–794)  &  5  471 (390–585)  &  –47 (–220–128)  &  0.225  |
| P  0.249  &  0.247  &  0.082  |
|                                              |
| STEO standard ellipse (cm²)                  |
| IG  6  3.6 (1.6–8.0)  &  6  4.4 (2.8–6.8)  &  0.9 (–1.1–2.3)  &  0.345  |
| CG  5  2.3 (0.8–7.7)  &  5  3.6 (0.8–4.4)  &  0.3 (–1.5–2.9)  &  0.893  |
| P  0.249  &  0.247  &  0.622  |
|                                              |
| STEC sway path (mm)                          |
| IG  6  1117 (656–1386)  &  6  1203 (668–1503)  &  88 (49–214)  &  0.028*  |
| CG  5  888 (13–2171)  &  5  935 (655–1672)  &  –142 (–500–122)  &  0.345  |
| P  0.792  &  0.429  &  0.126  |
|                                              |
| STEC standard ellipse (cm²)                  |
| IG  6  9.9 (3.2–12.2)  &  6  9.4 (2.5–11.3)  &  0.5 (–3.2–3.2)  &  0.753  |
| CG  5  5.1 (2.7–11.5)  &  5  5.2 (1.7–9.1)  &  –0.9 (–2.4–0.6)  &  0.225  |
| P  0.177  &  0.126  &  0.931  |
|                                              |
| MSEO sway path (mm)                          |
| IG  6  1621 (1295–2350)  &  4  1360 (926–2462)  &  –125 (–482–176)  &  0.465  |
| CG  5  1394 (1264–2111)  &  5  1546 (1254–1731)  &  –53 (–379–273)  &  0.500  |
| P  0.429  &  0.556  &  1.00  |
|                                              |
| MSEO standard ellipse (cm²)                  |
| IG  6  8.0 (6.6–16.9)  &  4  5.3 (3.6–8.1)  &  –3.2 (–11.6–11.0)  &  0.068  |
| CG  5  6.1 (3.9–8.3)  &  5  5.5 (3.8–8.8)  &  –0.1 (–1.1–1.5)  &  0.500  |
| P  0.177  &  0.730  &  0.063  |
|                                              |
| Mobility (TUG)                               |
|                                              |
| Duration (sec)                               |
| IG  6  6.2 (3.7–10)  &  6  5.2 (2.9–7.7)  &  –1.3 (–2.5–0.7)  &  0.027*  |
| CG  5  5.9 (4.5–17)  &  5  5.5 (4.8–10.6)  &  –1.1 (–6.4–1.1)  &  0.138  |
| P  0.662  &  0.329  &  1.00  |

*indicates a significant difference (p < 0.05); †prescribes the treatment effect by point estimation and 95% confidence interval of the Hodges-Lehmann's median differences for paired groups; STEO semi-tandem stance with eyes open, STEC semi-tandem stance with eyes closed, MSEO monopedal stance with eyes open, MSEC monopedal stance with eyes closed, TUG timed-up-and-go test.
cycle, which in turn is affected by the stretch-shortening cycle's efficacy [64, 65] and the level of reactive strength so essential for common daily situations such as adequate reactions to unexpected perturbations [66, 67]. WBV induces frequency-dependent, repeated muscle contractions culminating in a tonic vibration reflex that enhances the recruitment of motor units [26, 27] and that may improve the stretch-shortening cycle and inter- and intramuscular coordination. Reactive strength is more likely to depend on neuromuscular processes than on muscle size [68] and thus represents a clear functional gain. For example, reactive strength is an influencing variable of walking speed, one acknowledged predictor of mortality [9, 69, 70]. Consequently, enhanced jumping performance means improved interaction of muscles, tendons, and the neuromuscular system and therefore better functioning of the locomotoric system. The functional gains due to WBV are also visible in the improved performance on the TUG test. TUG is a common clinical test to evaluate patients’ mobility [71]. The time needed to complete this task strongly correlates with the independence during daily activities [46]. Thus, enhancing this ability is a crucial factor for a patient's autonomy. CRT performance, also a common clinical test for daily activity function and lower body strength [71], remained stable on a level comparable to age-adjusted reference values [40, 46]. Taking into account that the IG and CG carried out five respectively six exercise sessions during 27 days of hospitalization, we assume that the amount and intensity of WBV exercise sessions were insufficient to significantly affect lower-body strength. But we believe that our WBV intervention could enhance neuromuscular interaction and inter- and intramuscular coordination, in line with findings of Perchthaler et al. (2015) [72]. In general, inter- and intramuscular coordination is enhanced prior to considerable increases in strength [73, 74]. Accordingly, we presume that a longer intervention period with consequently more exercise sessions would also reveal group effects over time. Moreover, we propose evaluating muscle strength and function in greater detail to confirm our preliminary findings. Overall, preserving or even improving functional performance should be of particular interest when exercising with cancer patients receiving medical treatment, because there is ample evidence that functional impairments are highly relevant prognostic factors for survival [11]. Factors such as long periods of inactivity [6, 31, 75], neurotoxic agents among chemotherapy [76] or aging itself [45] lead to difficulty connecting sensory information and motor action [77]. This often results in impaired postural control and balance performance - determinants of functional status and significant risk factors for falls [78, 79]. We speculated that the repetitive stimuli of external perturbation induced by WBV would positively affect posture stability [62, 80]. In this context, Streckmann et al. (2018) [37] are even investigating WBV’s preventive effect on neuro-pathic symptoms, including postural stability, in patients undergoing neurotoxic chemotherapy. However, against our expectations, our balance-control analysis revealed that WBV was not superior to aerobic exercise. During the semi-tandem stance after intervention, IG’s sway path was even augmented. According to two reviews, WBV’s effects on balance performance remain inconsistent [81, 82]. Muehlbauer et al. [83] defined balance control and lower-extremity strength as independent neuromuscular systems that should be exercised separately. In conclusion, we propose that specific balance exercises be included that may prevent or even reduce balance impairments during hospitalization and thus further lower the risk of adverse health events [84]. Considering the non-significant post-intervention group effects, we cannot explicitly assume WBV’s superiority to aerobic exercises. However, the functional improvements we observed exclusively in our IG support the hypothesis that WBV has greater influence on neuromuscular adaption than aerobic cycling.

Conclusion
To best of our knowledge, our prospective, randomized controlled pilot study is the first study proving the feasibility of WBV immediate during intensive or high-dose chemotherapy in hospitalized cancer patients. Our results also suggest that WBV can improve mobility and jumping height in these patients. Such factors might be associated with greater autonomy and even better survival prognosis.
We thus recommend implementing WBV as an alternative training method to aerobic exercise training during intensive chemotherapy to maintain patients’ functional status. However, the specific advantages and relative benefits compared to other forms of resistance training require further investigation in greater detail and with larger sample sizes. The success we have had in our pilot study paves the way for further WBV-based investigations during chemotherapy.

Abbreviations
CG: Control group; CI: Confidence interval; CMJ: Counter movement jump; COF: Center of force; CRT: Chair rising test; EC: Eyes closed; EO: Eyes open; IG: Intervention group; TUG: Timed-up-and-go; WBV: Whole body vibration

Acknowledgements
We thank the staff of the Holthusen ward for their collaboration, and all patients for their participation. Furthermore we thank Elisa Straub for supporting us for exercise sessions and assessments. The article processing charge was funded by the German Research Foundation (DFG) and the Albert Ludwigs University Freiburg in the funding program Open Access Publishing.

Availability of data and materials
This article only includes summarized data of this study. Raw data is available from the corresponding author upon reasonable request.

Authors’ contributions
AP recruited patients, collected data, did the data analysis and interpretation of the data and drafted the manuscript. AW and SK designed the study, supervised the measurement and provided assistance for the data analysis and interpretation as well as drafting of the manuscript. AG and HB participated in the design of the study and revised the manuscript. HB did the medical clarification for patients’ study participation. All authors made contributions to the paper, are in agreement with the content and read the final manuscript.

Ethics approval and consent to participate
Ethics approval was given by the Ethics Committee of the University of Freiburg (267/12). Every patient had to sign written informed consent prior to inclusion.

Consent for publication
Not applicable.

Competing interests
The authors have no competing interests to declare.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Medicine I (Specialties: Hematology, Oncology, and Stem-Cell Transplantation), Faculty of Medicine, Medical Center – University of Freiburg, Hugstetterstr. 55, 79106 Freiburg, Germany. 2Institute for Exercise- and Occupational Medicine, Faculty of Medicine, Medical Center – University of Freiburg, Freiburg, Germany. 3Department of Sport and Sport Science, University of Freiburg, Freiburg, Germany.

Received: 29 January 2018 Accepted: 12 September 2018 Published online: 25 September 2018

References
1. de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ipoliti C, et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood. 2004;104:865–72.
2. Eba HP. Prognostic factors in elderly patients with AML and the implications for treatment. Hematol Am Soc Hematol Educ Program. 2007;1:420–8.
3. Reich G, Mapara MY, Reichardt P, Dörken B, Maschmeyer G. Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: comparison between patients with lymphoma or multiple myeloma and patients with solid tumors. Bone Marrow Transplant. 2001;27:525–9.
4. Evesuendo RB, Ratan M. Principles of Cancer chemotherapy. In: Vokes EE, Golomb HM, editors. Oncologic therapies. Berlin: Springer Berlin Heidelberg; 2013. p. 19–66. https://doi.org/10.1007/978-3-642-55780-4_3.
5. Buehring B, Belavý DL, Michælls I, Gast U, Felsenberg D, Rittweger J. Changes in lower extremity muscle function after 56 days of bed rest. J Appl Physiol. 2011;111:87–94.
6. Rittweger J, Frost H, Schüssel H, Oshihama H, Alkner B, Tesch P, et al. Muscle atrophy and bone loss after 90 days’ bed rest and the effects of flywheel resistive exercise and pamidronate: results from the LTBR study. Bone. 2005;36:1015–20.
7. Rejeski WJ, King AC, Katula JA, Kritchevsky S, King NS, Lipson SH, et al. Physical activity in older adults: a comprehensive review of its health benefits. J Am Geriatr Soc. 2009;57:251–9.
8. Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamontagne M, Lee IM, et al. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. Med Sci Sports Exerc. 2011;43:1334–59.
9. Cesari M, Krütschvily SB, Newman AB, Simonsick EM, Harris TB, Penninx BW, et al. Added value of physical performance measures in predicting adverse health-related events: results from the health, aging and body composition study. J Am Geriatr Soc. 2009;57:251–9.
10. Urbain P, Burlinger J, Lambert C, Finke J, Bartz H, Biesalski H-K. Longitudinal changes of nutritional status and its influencing factors in adults undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2013;48:446–51.
11. Brown JC, Harhay MO, Harhay MN. Physical function as a prognostic biomarker among cancer survivors. Br J Cancer. 2015;112:194–8.
12. Counsey KS, Friedenreich CM. Physical activity and cancer. Berlin: Springer; 2011.
13. Brown JC, Winters-Stone K, Lee A, Schmitz KH. Cancer, physical activity, and exercise. Compr Physiol. 2012;2:775–809.
14. Schmitz KH, Counsey KS, Matthews C, Derman-Wahnefried W, DA GO, Pinto BM, et al. American College of Sports Medicine Rundtable on Exercise Guidelines for Cancer Survivors. Med Sci Sports Exerc. 2010;42:1409–26.
15. Chang P-H, Lai Y-H, Shun S-C, Lin L-Y, Chen M-L, Yang Y, et al. Effects of a walking intervention on fatigue-related experiences of hospitalized acute myelogenous leukemia patients undergoing chemotherapy: a randomized controlled trial. J Pain Symptom Manag. 2008;35:524–34.
16. Dimeo F, Fetscher S, Lange W, Mertelsmann R, Keul J. Effects of aerobic exercise on the physical performance and incidence of treatment-related complications after high-dose chemotherapy. Blood. 1997;90:3390–4.
17. Coleman EA, Coon SK, Kennedy RL, Lochman KD, Stewart CB, Anaisie EJ, et al. Effects of exercise in combination with epoetin alfa during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for multiple myeloma. Oncol Nurs Forum. 2008;35:E53–61.
18. Baumann FT, Zapf EM, Nykamp E, Kraut L, Schüle K, Elter T, et al. Physical activity for patients undergoing an allogeneic hematopoietic stem cell transplantation: benefits of a moderate exercise intervention. Eur J Haematol. 2011;87:48–56.
19. Wiskemann J, Drexler P, Schwertfeger R, Bondong A, Huber G, Kleindienst N, et al. Effects of a partly self-administered exercise program before, during, and after allogeneic stem cell transplantation. Blood. 2011;117:2604–13.
20. Mello M, Tanaka C, Dulley FL. Effects of an exercise program on muscle performance in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant. 2003;32:723–8.
21. Cunningham BA, Norris G, Cheney CL, Buerger N, Aker SN, Lassen P. Effects of resistive exercise on skeletal muscle in marrow transplant recipients receiving total parenteral nutrition. JPN J Parenter Enteral Nutr. 1986;10:558–63.
22. Morley JE, Thomas DR, Wilson M-MG. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr. 2006;83:735–43.
69. Onder G, Penninx BWJH, Ferrucci L, Fried LP, Guralnik JM, Pahor M. Measures of physical performance and risk for progressive and catastrophic disability: results from the Women’s health and aging study. J Gerontol A Biol Sci Med Sci. 2005;60:74–9.

70. Klepin HD, Geiger AM, Tooze JA, Newman AB, Colbert LH, Bauer DC, et al. Physical performance and subsequent disability and survival in older adults with malignancy: results from the health, aging and body composition study. J Am Geriatr Soc. 2010;58:76–82.

71. Jones CJ, Rikli RE, Beam WC. A 30-s chair-stand test as a measure of lower body strength in community-residing older adults. Res Q Exerc Sport. 1999;70:113–9.

72. Perchhailer D, Grau S, Hein T. Evaluation of a six-week whole-body vibration intervention on neuromuscular performance in older adults. J Strength Cond Res. 2015;29:86–95.

73. Häkkinen K, Komi PV. Electromyographic changes during strength training and detraining. Med Sci Sports Exerc. 1983;15:455–60.

74. Rutherford OM, Jones DA. The role of learning and coordination in strength training. Eur J Appl Physiol. 1986;55:100–5.

75. Muir J, Judex S, Qin Y-X, Rubin C. Postural instability caused by extended bed rest is alleviated by brief daily exposure to low magnitude mechanical signals. Gait Posture. 2011;33:429–35.

76. Winters-Stone KM, Horak F, Jacobs PG, Trubowitz P, Dieckmann NF, Stoyles S, et al. Falls, functioning, and disability among women with persistent symptoms of chemotherapy-induced peripheral neuropathy. J Clin Oncol. 2017;35:2604–12.

77. Prioli AC, Freitas Júnior PB, Barela JA. Physical activity and postural control in the elderly: coupling between visual information and body sway. Gerontology. 2005;51:145–8.

78. Ward RE, Leveille SG, Beauchamp MK, Travison T, Alexander N, Jette AM, et al. Functional performance as a predictor of injurious falls in older adults. J Am Geriatr Soc. 2015;63:315–20.

79. Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. N Engl J Med. 1988;319:1701–7.

80. Bogaerts A, Verschueren S, Delecluse C, Claessens AL, Boonen S. Effects of whole body vibration training on postural control in older individuals: a 1 year randomized controlled trial. Gait Posture. 2007;26:309–16.

81. Lam FMH, Lau RWK, Chung RCK, Pang MYC. The effect of whole body vibration on balance, mobility and falls in older adults: a systematic review and meta-analysis. Maturitas. 2012;72:206–13.

82. Orr R. The effect of whole body vibration exposure on balance and functional mobility in older adults: a systematic review and meta-analysis. Maturitas. 2015;80:342–58.

83. Muehlbauer T, Gollhofer A, Granacher U. Associations between measures of balance and lower-extremity muscle strength/power in healthy individuals across the lifespan: a systematic review and meta-analysis. Sports Med Auckl NZ. 2015;45:1671–92.

84. Rubenstein LZ. Falls in older people: epidemiology, risk factors and strategies for prevention. Age Ageing. 2006;35(Suppl 2):ii37–41.